As of May, 7 ZIOPHARM Oncology, Inc. (ZIOP) EPS Estimated At $-0.13

April 16, 2018 - By Elizabeth Jones

Investors expect ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP)’s quarterly earnings on May, 7., Zacks reports. The earnings per share diference is $0.02 or 13.33 % up from last years number. Previous year: $-0.15; Analysts forcast: $-0.13. After $-0.13 EPS report last quarter, Wall Street now forecasts 0.00 % EPS growth of ZIOPHARM Oncology, Inc.. The stock decreased 3.35% or $0.15 during the last trading session, reaching $4.33.ZIOPHARM Oncology, Inc. has volume of 623,237 shares. Since April 16, 2017 ZIOP has declined 39.46% and is downtrending. ZIOP underperformed the S&P 500 by 51.01%.

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Ratings Coverage

In total 2 analysts cover Ziopharm Oncology (NASDAQ:ZIOP). “Buy” rating has 1, “Sell” are 0, while 1 are “Hold”. 50% are bullish. 3 are the (NASDAQ:ZIOP)’s analyst reports since December 11, 2017 according to StockzIntelligence Inc. On Thursday, December 14 the stock of ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) earned “Buy” rating by H.C. Wainwright. On Monday, March 5 the stock of ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) has “Buy” rating given by H.C. Wainwright.

ZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of cancer therapies that address unmet medical needs through synthetic immuno-oncology.The firm is worth $610.44 million. The company, through its collaboration agreement with Intrexon Corporation, holds certain rights to Intrexon??s synthetic immuno-oncology platform for use in the field of oncology, which includes a clinical stage product candidate, Ad-RTS-IL-12 evaluated for the treatment of metastatic melanoma, unresectable recurrent or metastatic breast cancer, and Grade III malignant glioma .Currently it has negative earnings. The Company’s synthetic immuno-oncology platform employs an inducible gene-delivery system that enables controlled in vivo expression of genes that produce therapeutic proteins to treat cancer.

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: